TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00803218

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.005% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of one day

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.005% Ointment-Reference Product
Description: Small amount applied and evaluated over the course of one day

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.005% Ointment-Test product
Description: Small amount applied and evaluated over the course of one day

Intervention type: DRUG
Intervention: Fluticasone Propionate 0.005% Ointment-Test product
Description: Small amount applied and evaluated over the course of one day
Study: NCT01911637

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VBY-036
Description: Study drug VBY-036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBY-036
Description: Study drug VBY-036

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01943708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPAP
Description: Novel Auto-algorithm for Auto-CPAP device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Standard CPAP therapy
Study: NCT02590302

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation Phase
Description: Core Components of the implementation intervention include:~* Hospital and CMHA project commitment~* Site champion teams (from hospital and CMHA)~* Memorandum of Agreement between Hospital and CMHA~* Pre-intervention site visits~* Education sessions~* Posters/reminders~* Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site.
Study: NCT01732731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: treadmill training
Description: Home-based treadmill training will be administered to the children in the experimental group
Study: NCT00847119

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda)
Description: Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Rectal Radiotherapy
Description: Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
Study: NCT00107926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licarbazepine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01496768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 7,2 g/day during 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: 7,2 g/day during 3 months
Study: NCT01165190

Intervention type: OTHER
Intervention: pioglitazone
Study: NCT00930982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro, BAYQ3939)
Description: Inhalation of 32,5mg Ciprofloxacin inhaled twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation of matching placebo twice a day
Study: NCT03730454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanastomotic Tube (5FR)
Description: 5FR tube left in place for 5 days after completion of esophageal anastomosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Transanastomotic Tube
Description: No transanastomotic tube used during repair
Study: NCT02272543

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish surimi peptide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish surimi peptide
Study: NCT02557438

Intervention type: PROCEDURE
Intervention: Roux-en-Y Gastric Bypass
Description: Determination of the kind of surgery will be made by the participant's providers and not by study staff

Intervention type: PROCEDURE
Intervention: Vertical Sleeve Gastrectomy
Description: Determination of the kind of surgery will be made by the participant's providers and not by study staff
Study: NCT00519246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid
Description: Tramadol Hydrochloride 20 mg i.v.
Study: NCT04092283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT01501149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
Description: MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Study: NCT00650429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
Study: NCT04641546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.
Study: NCT04576481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texting
Description: Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: Text Messages will be sent to participants using Penn's Way to Health Platform. Participants will be asked to reply to daily text messages on daily shared reading activities including the titles of books and time spent reading.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret
Description: Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret
Description: Personalized coaching content will be made available to participants through links in the text messages and will provide comparisons of their reading frequency with that of other participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery
Description: Participants who reply to a text message that they read on a particular day will be entered into daily and weekly drawings to receive cash payments.
Study: NCT04624204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Pembrolizumab 200 mg Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Pembrolizumab 200 mg Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg
Description: Pembrolizumab 400 mg Q6W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg
Description: Pembrolizumab 400 mg Q6W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab placebo (saline)
Description: Pembrolizumab placebo (saline) Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab placebo (saline)
Description: Pembrolizumab placebo (saline) Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg BID
Description: Olaparib 300 mg twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib matching placebo
Description: Olaparib matching placebo BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olaparib matching placebo
Description: Olaparib matching placebo BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m^2
Description: Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
Study: NCT04641546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Passive range of motion (PROM), active-assistive range of motion (AAROM), active range of motion (AROM), and strengthening activities.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occupation-Based Intervention
Description: Collecting and placing items in cabinets, washing windows and tables, and hanging clothes on a clothesline.
Study: NCT00105729

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive referral to 12-step self-help groups
Study: NCT04929873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closed transdyser
Description: When the average arterial pressure ≥ 50mmHg, it is indicated that the basic blood supply of the lower extremities is satisfied without special treatment, and when the average arterial pressure \< 50mmHg, it indicates insufficient perfusion, by adjusting the pipe position, changing the ECMO flow rate, and properly clamping the artery end to divert part of the blood flow to the side branch circulation, so that the average arterial pressure is maintained above 50mmHg.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine monitor
Description: Obtain oxygen saturation, skin color, temperature, etc
Study: NCT04546256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 500/50
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT02046564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04303585

Intervention type: PROCEDURE
Intervention: SAP block
Description: The anesthesiologist performs SAP block immediately before surgery under ultrasound guide

Intervention type: PROCEDURE
Intervention: ESP block
Description: The anesthesiologist performs ESP block immediately before surgery under ultrasound guide
Study: NCT04624204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m^2
Description: Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide 100 mg/m^2
Description: Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum, investigator's choice
Description: Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum, investigator's choice
Description: Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum, investigator's choice
Description: Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Thoracic Radiotherapy
Description: Standard Thoracic Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Thoracic Radiotherapy
Description: Standard Thoracic Radiotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Standard Thoracic Radiotherapy
Description: Standard Thoracic Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study: NCT01481571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrification medium oocyte, warming medium oocyte and Rapid-i
Description: Media and device for vitrification of human oocytes
Study: NCT04624204

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: PCI will be strongly recommended for participants who achieve CR or PR after completion of chemoradiation treatment.
Study: NCT01744418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAVG graft implantation
Description: Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
Study: NCT04652882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT03390673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD204
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
Study: NCT02531100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BonyPid 500TM implantation concomitantly to SOC treatment
Description: BonyPid 500TM implantation concomitantly to SOC treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC treatment only
Description: Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)

Intervention type: OTHER
Group type: OTHER
Intervention: SOC treatment only
Description: Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
Study: NCT02416310

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
Study: NCT03935399

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: 10 IU oxytocin (Pitocin) for intramuscular injection
Study: NCT01293955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JOINS 200mg
Description: 1 tablet at each time, 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo of Joins 200mg
Study: NCT04092283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study: NCT03162536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.
Study: NCT03031730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Sodium Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO
Study: NCT02384343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
Study: NCT02810132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: See above

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See above
Study: NCT02201628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal and oesophageal temperature probes
Study: NCT02809781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of MSCs
Description: Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
Study: NCT04092283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT02809781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: 50mg,hypodermic injection,once per week, for 12 weeks
Study: NCT04092283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT03046550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTM-1634
Description: NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT04092283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study: NCT01899378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: 10\^8 CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: 10\^8 CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: 10\^8 CFU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum infantis
Description: 10\^9 CFU
Study: NCT04092283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study: NCT04417660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Bintrafusp alfa will be administered at a dose of 1200 mg intravenously once every two weeks until disease progression or development of intolerable adverse events.
Study: NCT02986737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACURATE neo™ and ACURATE TA™ LP
Description: ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
Study: NCT00719173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: Given orally
Study: NCT03840837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Description: Titration of transdermal rivastigmine, as per arm description.
Study: NCT03046550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo